BD Names CEO Tom Polen as Chairman of the Board
On January 26, 2021, BD (Becton, Dickinson and Company) announced that Tom Polen, current CEO, will also become chairman of the board effective April 28, 2021. He succeeds Vincent A. Forlenza, retiring after leading BD through significant transformations. Under Polen's leadership, BD expanded its role during the COVID-19 pandemic by enhancing diagnostic testing and manufacturing essential medical supplies. Polen, with over 20 years at BD, aims to drive the BD 2025 strategy focused on growth, simplification, and empowerment to improve global healthcare delivery.
- Tom Polen assumed dual roles as CEO and chairman, signaling continuity in leadership.
- Polen's leadership during the COVID-19 pandemic led to increased production of syringes and successful scaling of diagnostic testing.
- The transition occurs after Forlenza's notable legacy of significant acquisitions, strengthening BD's market position.
- None.
FRANKLIN LAKES, N.J., Jan. 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Tom Polen, BD CEO and president, will assume additional responsibility as chairman of the BD board of directors, effective April 28, 2021. Polen will succeed Vincent A. Forlenza, who will retire from BD at that time.
"In Tom's first year as CEO, he faced unprecedented challenges from the global COVID-19 pandemic, and successfully guided the company to assist in the pandemic, while also advancing the focus and commitment to quality and compliance across the organization," said Marshall Larsen, lead director for the BD board. "Under his leadership, BD developed and rapidly scaled COVID-19 diagnostic testing, increased manufacturing for syringes and needles to meet the needs for worldwide COVID-19 vaccination campaigns and ensured BD's full spectrum of critical innovations continued to reach patients around the globe. Tom and his leadership team also advanced several important strategic initiatives during his first year as CEO. The results are a testament to his leadership and decisive actions. BD will be well served with Tom as chairman of the board.
"I'd also like to thank Vince for his lifetime commitment to making BD a better company for its customers, employees and investors," Larsen continued. "Vince led the company through its greatest transformation in its more than 120-year history. The culmination of Vince's legacy included the acquisitions of CareFusion and C. R. Bard, which expanded BD's ability to serve more patients and increased the company's relevance to its global customers. We wish Vince and his family the very best in his retirement."
Polen, [47], joined BD in 1999, and has held a variety of leadership roles at numerous business units. He was appointed president of BD in April 2017, was named chief operating officer in October 2018 and became CEO in January 2020.
"It is truly an honor to lead this innovative company, particularly at this critical time in the health care industry," said Polen. "BD's success has always been a collective achievement, driven by the hard work and unwavering commitment of our employees around the globe. I'm proud of the way our team has responded to the greatest health care crisis in a century by rallying around the company's purpose and embracing the values that drive the culture of growth through innovation, quality and compliance across our organization. We will continue to rely on their passion and support to help us in advancing the world of health for our customers and their patients. I look forward to working with our board of directors and the global BD team to continue to drive the BD 2025 strategy of Grow, Simplify and Empower."
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.
Contacts: | |
Troy Kirkpatrick | Kristen M. Stewart, CFA 201.847.5378 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-names-ceo-tom-polen-as-chairman-of-the-board-301214616.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
When will Tom Polen become chairman of BD?
Who is succeeding Vincent A. Forlenza at BD?
What major changes occurred in BD's leadership in 2021?
How did BD respond to the COVID-19 pandemic under Tom Polen's leadership?
What is the BD 2025 strategy mentioned by Tom Polen?
